{
  "slug": "glp1-anesthesia-aspiration",
  "question": "If you take a GLP-1 drug, will retained stomach contents cause you to aspirate during general anesthesia?",
  "category": "health",
  "tags": [
    "substance-use"
  ],
  "no_reliable_estimate": false,
  "perceived": {
    "description": "Press coverage of the 2023 ASA advisory and the November 2024 FDA label warning framed GLP-1 drugs as a serious anesthesia hazard, with headlines urging patients to stop Ozempic or risk aspirating during surgery. The intuitive read is that a GLP-1 user faces a high, near-certain chance of choking on retained stomach contents on the operating table. No survey has measured this specific perception, so the rough estimate is inferred from the alarm in coverage and patient forums, not from polling.",
    "rough_estimate": "Patients and media framing imply a perceived per-procedure aspiration risk on the order of several percent to tens of percent ('don't go under on Ozempic').",
    "kind": "intuition"
  },
  "native": {
    "display": "about 1 in 610 procedures",
    "numerator": 143,
    "denominator": 87691,
    "unit": "GLP-1 users undergoing elective endoscopy under sedation/anesthesia",
    "population": "Adults taking a GLP-1 receptor agonist who undergo an elective procedure requiring general anesthesia or deep sedation"
  },
  "normalized": {
    "lifetime_us_adult": 0.00163,
    "display": "about 1 in 610 per procedure",
    "log_value": -2.788,
    "assumptions": "Subgroup: an adult on a GLP-1 receptor agonist undergoing one elective procedure requiring general anesthesia or deep sedation. Basis: PER PROCEDURE, not aggregated over a lifetime of procedures. Point estimate 0.00163 is the pooled aspiration rate in GLP-1 users from the largest endoscopy meta-analysis (143/87,691 = 0.00163). The uncertainty band spans the range of real-world cohorts: the lower bound (~0.0008) approaches the general-population GA baseline (~1 in 8,325 = 0.00012 to ~1 in 2,500 = 0.0004) and the lower cohort estimates; the upper bound (~0.008) reflects the surgical cohort figure of 0.8% (IJS 2025). Crucially this is the ABSOLUTE per-procedure aspiration probability, NOT a GLP-1-attributable excess: the matched control rates (0.12%-0.7%) overlap the GLP-1 rates, and pooled odds ratios (1.07-1.23) are not statistically significant. So the headline number is 'how often a GLP-1 user aspirates,' which is low, while 'how much the drug raises that risk' is null-to-unproven.",
    "uncertainty": {
      "low": 0.0008,
      "high": 0.008
    },
    "scope": "subgroup_lifetime"
  },
  "sources": [
    {
      "url": "https://jamanetwork.com/journals/jamasurgery/fullarticle/2815663",
      "title": "Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia",
      "publisher": "JAMA Surgery",
      "source_type": "peer_reviewed",
      "statistic": "GLP-1 RA use associated with a 30.5% (95% CI, 9.9%-51.2%) higher prevalence of increased residual gastric content; 56% (35/62) vs 19% (12/62).",
      "excerpt": "GLP-1 RA use was associated with a 30.5% (95% CI, 9.9%-51.2%) higher prevalence of increased RGC",
      "source_date": "2024-03-06",
      "source_accessed": "2026-06-13",
      "calculation_notes": "This is the SURROGATE (retained gastric content), not aspiration. Raw prevalence 56% vs 19%; adjusted difference +30.5%. Increased RGC defined as solids, thick liquids, or >1.5 mL/kg clear liquids on ultrasound. Authors note they 'did not directly assess aspiration events, which are rare.' Used to establish the elevated-surrogate half of the perceived-vs-actual gap, not the headline number.",
      "independence_note": "University of Texas Houston cohort; independent of the endoscopy and surgery aspiration cohorts below."
    },
    {
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12481593/",
      "title": "GLP-1 Agonists and the Risk of Pulmonary Aspiration during Elective Upper Endoscopy: A Systematic Review and Meta-analysis",
      "publisher": "The Open Respiratory Medicine Journal",
      "source_type": "peer_reviewed",
      "statistic": "Pulmonary aspiration in 143/87,691 (0.16%) GLP-1 users vs 149/122,525 (0.12%) controls; OR 1.23 (95% CI 0.58-2.60; P=0.59), not significant.",
      "excerpt": "143 of 87,691 patients (0.16%) in the GLP-1 agonist group and 149 of 122,525 patients (0.12%) in the placebo group had pulmonary aspiration.",
      "source_date": "2025-06-11",
      "source_accessed": "2026-06-13",
      "calculation_notes": "Source of the native counts and the normalized point estimate. 143/87,691 = 0.00163. Control rate 149/122,525 = 0.00122 overlaps, OR 1.23 not significant -> the absolute rate is low and the excess is unproven. Point estimate = 0.00163; log10 = -2.788.",
      "independence_note": "Pooled endoscopy meta-analysis; distinct dataset from the surgical TriNetX/IJS cohorts."
    },
    {
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12165584/",
      "title": "Glucagon-like-peptide-1 (GLP-1) receptor agonist use and the risk of pulmonary aspiration in patients undergoing surgery",
      "publisher": "International Journal of Surgery",
      "source_type": "peer_reviewed",
      "statistic": "Aspiration 0.8% in GLP-1 users vs 0.7% non-users (P=0.61); adjusted OR 1.07 (95% CI 0.85-1.34), no association. N=392,065 (15,745 users).",
      "excerpt": "After adjusting for other risk factors for aspiration, there was no association between GLP-1 agonist use and aspiration (OR = 1.07; 95% CI, 0.85–1.34).",
      "source_date": "2025-05-12",
      "source_accessed": "2026-06-13",
      "calculation_notes": "Supplies the upper end of the uncertainty band (0.8% = 0.008). Surgical population (2015-2022), broader than endoscopy, so higher absolute aspiration rate. Confirms the null excess: OR 1.07 not significant.",
      "independence_note": "Separate surgical cohort; conclusion converges with the endoscopy meta despite independent data."
    },
    {
      "url": "https://academic.oup.com/jes/article/9/9/bvaf088/8196040",
      "title": "Glucagon-Like Peptide-1 Receptor Agonists and Peri-Procedural Aspiration Risk",
      "publisher": "Journal of the Endocrine Society",
      "source_type": "peer_reviewed",
      "statistic": "Across cohorts, aspiration ~2.6-8.3 per 1000 in GLP-1 users vs similar in non-users; retained-content risk ratios 2.92-15.14; ASA Oct 29 2024 guidance.",
      "excerpt": "retrospective cohort studies using large real-world evidence databases have not consistently identified a GLP-1RA-associated risk of aspiration/pneumonia for elective surgical and endoscopic procedures",
      "source_date": "2025-07-10",
      "source_accessed": "2026-06-13",
      "calculation_notes": "Review consolidating the field: per-procedure aspiration 2.61-8.32 per 1000 in users (0.0026-0.0083), bracketing the chosen band; retained-content RRs 2.92-15.14 (the elevated surrogate). Source for the multisociety guidance summary and the 'continue most patients, shared decision making' framing.",
      "independence_note": "Narrative review summarizing the primary cohorts above; cited for synthesis and guidance context, not as an independent dataset."
    },
    {
      "url": "https://apm.amegroups.org/article/view/65476/html",
      "title": "Perioperative pulmonary aspiration and regurgitation without aspiration in adults: a retrospective observational study of 166,491 anesthesia records",
      "publisher": "Annals of Palliative Medicine",
      "source_type": "peer_reviewed",
      "statistic": "Perioperative aspiration in 20/166,491 anesthetics (1:8,325); morbidity 1:16,649; mortality 1:55,497.",
      "excerpt": "Among the 166,491 anesthesia records, 20 patients had PA (1:8,325)",
      "source_date": "2021-04-30",
      "source_accessed": "2026-06-13",
      "calculation_notes": "General-population baseline aspiration rate under anesthesia (1:8,325 = 0.00012), pre-dating the GLP-1 era. Establishes the lower edge / reference point: GLP-1-user rates (0.0016-0.008) sit near or modestly above this baseline, consistent with the null-excess finding. Used for the lower uncertainty bound and severity context.",
      "independence_note": "Baseline cohort with no GLP-1 exposure measured; independent of all GLP-1 sources."
    },
    {
      "url": "https://www.pharmacytimes.com/view/fda-adds-delayed-gastric-emptying-as-adverse-event-on-semaglutide-label",
      "title": "FDA Adds Delayed Gastric Emptying as Adverse Event on Semaglutide Label",
      "publisher": "Pharmacy Times",
      "source_type": "news_article",
      "statistic": "FDA added a label warning of rare postmarketing reports of pulmonary aspiration in GLP-1 users undergoing anesthesia despite reported fasting (Nov 2024).",
      "excerpt": "postmarking reports showing rare instances of pulmonary aspiration for patients receiving glucagon-like peptide-1 (GLP-1) receptor agonists and undergoing elective surgeries or procedures that require general anesthesia or deep sedation",
      "source_date": "2024-11-14",
      "source_accessed": "2026-06-13",
      "calculation_notes": "Documents the FDA regulatory action (label 'rare instances' language) that drives the public-perception half of the entry. Non-authoritative news source; used only for the FDA/labeling timeline, not for any rate."
    }
  ],
  "comparison_anchors": [
    {
      "label": "Drowning (lifetime, US)",
      "lifetime_us_adult": 0.000725
    },
    {
      "label": "Food poisoning death (lifetime, US)",
      "lifetime_us_adult": 0.000537
    },
    {
      "label": "Hospital-acquired infection (lifetime, US)",
      "lifetime_us_adult": 0.039
    }
  ],
  "personal_factor_multipliers": [
    {
      "factor": "Active GI symptoms (nausea, vomiting, bloating) at the time of the procedure",
      "multiplier": 2,
      "notes": "The 2024 multisociety guidance classifies GI symptoms, dose-escalation phase, weekly dosing, and higher doses as 'higher risk' for delayed gastric emptying; gastric-ultrasound studies show retained-content risk ratios from 2.92 to 15.14 in such users. Multiplier is a conservative directional estimate for the retained-content surrogate, not a measured aspiration multiplier."
    },
    {
      "factor": "Ultrasound-confirmed empty stomach after a clear-liquid diet / extended fast",
      "multiplier": 0.4,
      "notes": "Point-of-care gastric ultrasound that finds an empty antrum returns the patient to roughly the general-anesthesia baseline; the multisociety guidance treats a documented empty stomach as removing the GLP-1-specific concern. Protective direction; exact factor not measured for aspiration events."
    }
  ],
  "short_label": "GLP-1 anesthesia aspiration",
  "outcome_severity": "serious_harm",
  "exposure_pattern": "acute",
  "outcome_type": "serious_permanent_harm",
  "valence": "negative",
  "caveats": "The headline number is the absolute per-procedure aspiration rate for a GLP-1 user (about 1 in 610 in the endoscopy meta-analysis, up to about 1 in 125 in the broader surgical cohort), NOT the amount the drug adds to that risk. The two large real-world cohorts and the endoscopy meta-analysis found matched control rates that overlap the GLP-1 rates, with odds ratios (1.07, 1.23) that are not statistically significant, and one nationwide propensity-matched study found GLP-1 users had a lower aspiration rate than non-users. So the drug's attributable excess is null-to-unproven even though the surrogate (retained gastric contents) is markedly elevated (56% vs 19% on ultrasound; risk ratios 2.92 to 15.14). Aspiration events are rare, so per-procedure estimates rest on small numerators and wide confidence intervals; the surgical and endoscopy figures differ by procedure type, urgency, and airway management. The number is scoped per procedure, not per lifetime; a person undergoing many procedures accumulates risk roughly linearly. The 8D self-score clears threshold (avg 4.0), with the main soft spots being perception (intuition-only, no survey) and the per-procedure-vs-lifetime scope translation.",
  "quality_score": {
    "d1": 4,
    "d2": 5,
    "d3": 4,
    "d4": 4,
    "d5": 4,
    "d6": 4,
    "d7": 3,
    "d8": 4,
    "avg": 4,
    "scored_by": "claude-code-8d",
    "scored_at": "2026-06-13",
    "methodology_version": "8d-v1"
  },
  "reviewer": "8d-eval-2026-06-13",
  "last_reviewed": "2026-06-13",
  "reviewed": true,
  "generated_at": "2026-06-13",
  "image": {
    "alt": "An abstract editorial symbol evoking \"Aspiration under anesthesia on a GLP-1 drug\", muted two-tone palette, flat vector."
  },
  "attribution": "Likelier — https://likelier.app",
  "license": "https://creativecommons.org/licenses/by-sa/4.0/",
  "support": "https://buymeacoffee.com/kgluszczyk?via=likelier&utm_content=api-fear-single",
  "canonical_url": "https://likelier.app/glp1-anesthesia-aspiration"
}